Trial Profile
A 12 Month, Double Blind, Randomized, Placebo-controlled Trial Evaluating the Effect of BIBF 1120 Administered at Oral Doses of 50 mg qd, 50 mg Bid, 100 mg Bid and 150 mg Bid on Forced Vital Capacity Decline During One Year, in Patients With Idiopathic Pulmonary Fibrosis, With Optional Active Treatment Extension Until Last Patient Out
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 04 Sep 2023
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms TOMORROW
- Sponsors Boehringer Ingelheim
- 30 Aug 2023 Results of pooled analysis from NCT00514683, NCT01335464, NCT01335477, NCT01979952, NCT02999178, NCT02597933, assessing decline in forced vital capacity (FVC) as a surrogate for mortality, published in the Respirology
- 27 Dec 2021 Results published in the Advances in Therapy
- 19 May 2021 Results of pooled analysis (n=2553) assessing decline in forced vital capacity (FVC) as a surrogate for mortality from NCT00514683, NCT01335464, NCT01335477, NCT01979952, NCT02597933 and NCT02999178 trials, presented at the 117th International Conference of the American Thoracic Society.